奥美拉唑如何更好发挥药效

2018-03-16 张思玮 中国科学报

胃酸、胃疼、胃溃疡等肠胃疾病,很多人第一反应就会想到奥美拉唑。因为它能有效地减少胃酸分泌,改善胃部不适感。通常奥美拉唑分为口服剂型和静脉注射剂,我国批准的口服剂型非常多,有片剂、肠溶片、胶囊、肠溶胶囊等。“奥美拉唑是一种不耐酸的碱性药物,胃处于酸性环境。所以,一些老年人或者严重胃溃疡患者,首先应选肠溶剂,以发挥最大的药效。”北京大学人民医院临床药师夏雨建议,患者一般在清晨饭前半小时到1小时之间服用

胃酸、胃疼、胃溃疡等肠胃疾病,很多人第一反应就会想到奥美拉唑。因为它能有效地减少胃酸分泌,改善胃部不适感。通常奥美拉唑分为口服剂型和静脉注射剂,我国批准的口服剂型非常多,有片剂、肠溶片、胶囊、肠溶胶囊等。

“奥美拉唑是一种不耐酸的碱性药物,胃处于酸性环境。所以,一些老年人或者严重胃溃疡患者,首先应选肠溶剂,以发挥最大的药效。”北京大学人民医院临床药师夏雨建议,患者一般在清晨饭前半小时到1小时之间服用效果比较好,因为通常人的胃酸是早上分泌比较旺盛。当然,也有医生建议患者在晚上服用奥美拉唑,这是因为凌晨2点至5点之间,胃酸的分泌量会较多。

针对奥美拉唑的服药剂量和药程,夏雨表示,不同适应症的服用剂量和时长都是不一样的。比如反流性食管炎和胃溃疡,两者的用药剂量和药程就存在差异,胃溃疡是40毫克/天,4至8周,一般是4周左右;而反流性食管炎则为40~80毫克/天,8至12周,需要巩固治疗,否则难以抑制反流的形成。

特别需要注意的是,奥美拉唑会与一些药物产生明确的相互作用。比如,奥美拉唑肠溶片的吸收局限在小肠内,但有些药物却是作用于全消化道,如莫沙比利,它可以促进整个肠道的蠕动,加快胃的排出和食物的排出。如果两者同时服用,会导致奥美拉唑很快被排出,药效难以发挥。

“此外,奥美拉唑不可以和氯吡格雷同时服用。”夏雨解释,因为奥美拉唑与氯吡格雷的药效发挥作用都离不开CYP2C19基因的参与,两个药物同时服用就会影响药效。“这种情况,患者应优先选用雷贝拉唑和泮托拉唑。”

“任何药物长期服用都有副作用,胃病患者不能擅自增加疗程,否则可能会出现严重的不良反应。”夏雨说。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1672311, encodeId=294116e23111f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat May 12 05:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284406, encodeId=7b611284406e1, content=<a href='/topic/show?id=3db5445e031' target=_blank style='color:#2F92EE;'>#奥美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44570, encryptionId=3db5445e031, topicName=奥美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Mar 18 06:38:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297217, encodeId=870829e217dd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Mar 18 00:11:42 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297152, encodeId=5c6e29e152ea, content=学习了.感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Sat Mar 17 18:51:20 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296995, encodeId=fa50296995cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:41:13 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296992, encodeId=8a0029699257, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:37:11 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296871, encodeId=9b4b2968e1dd, content=一般用波立维的病人我们也是用波立特, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/16/a3f6b823a8478ec11f505fd146e211d9.jpg, createdBy=3d5e2288124, createdName=121dde13m89暂无昵称, createdTime=Fri Mar 16 21:12:19 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296857, encodeId=696129685e6f, content=确实好多病人都不会用药.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/20/325f09b1de43bf0f9a34e0f300559c38.jpg, createdBy=99df2253231, createdName=驹迷一生, createdTime=Fri Mar 16 18:59:25 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296838, encodeId=c4ff29683886, content=奥美拉唑的确应用.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 16 17:18:40 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-05-12 lsndxfj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1672311, encodeId=294116e23111f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat May 12 05:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284406, encodeId=7b611284406e1, content=<a href='/topic/show?id=3db5445e031' target=_blank style='color:#2F92EE;'>#奥美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44570, encryptionId=3db5445e031, topicName=奥美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Mar 18 06:38:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297217, encodeId=870829e217dd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Mar 18 00:11:42 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297152, encodeId=5c6e29e152ea, content=学习了.感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Sat Mar 17 18:51:20 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296995, encodeId=fa50296995cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:41:13 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296992, encodeId=8a0029699257, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:37:11 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296871, encodeId=9b4b2968e1dd, content=一般用波立维的病人我们也是用波立特, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/16/a3f6b823a8478ec11f505fd146e211d9.jpg, createdBy=3d5e2288124, createdName=121dde13m89暂无昵称, createdTime=Fri Mar 16 21:12:19 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296857, encodeId=696129685e6f, content=确实好多病人都不会用药.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/20/325f09b1de43bf0f9a34e0f300559c38.jpg, createdBy=99df2253231, createdName=驹迷一生, createdTime=Fri Mar 16 18:59:25 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296838, encodeId=c4ff29683886, content=奥美拉唑的确应用.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 16 17:18:40 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1672311, encodeId=294116e23111f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat May 12 05:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284406, encodeId=7b611284406e1, content=<a href='/topic/show?id=3db5445e031' target=_blank style='color:#2F92EE;'>#奥美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44570, encryptionId=3db5445e031, topicName=奥美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Mar 18 06:38:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297217, encodeId=870829e217dd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Mar 18 00:11:42 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297152, encodeId=5c6e29e152ea, content=学习了.感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Sat Mar 17 18:51:20 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296995, encodeId=fa50296995cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:41:13 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296992, encodeId=8a0029699257, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:37:11 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296871, encodeId=9b4b2968e1dd, content=一般用波立维的病人我们也是用波立特, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/16/a3f6b823a8478ec11f505fd146e211d9.jpg, createdBy=3d5e2288124, createdName=121dde13m89暂无昵称, createdTime=Fri Mar 16 21:12:19 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296857, encodeId=696129685e6f, content=确实好多病人都不会用药.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/20/325f09b1de43bf0f9a34e0f300559c38.jpg, createdBy=99df2253231, createdName=驹迷一生, createdTime=Fri Mar 16 18:59:25 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296838, encodeId=c4ff29683886, content=奥美拉唑的确应用.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 16 17:18:40 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-18 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1672311, encodeId=294116e23111f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat May 12 05:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284406, encodeId=7b611284406e1, content=<a href='/topic/show?id=3db5445e031' target=_blank style='color:#2F92EE;'>#奥美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44570, encryptionId=3db5445e031, topicName=奥美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Mar 18 06:38:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297217, encodeId=870829e217dd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Mar 18 00:11:42 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297152, encodeId=5c6e29e152ea, content=学习了.感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Sat Mar 17 18:51:20 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296995, encodeId=fa50296995cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:41:13 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296992, encodeId=8a0029699257, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:37:11 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296871, encodeId=9b4b2968e1dd, content=一般用波立维的病人我们也是用波立特, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/16/a3f6b823a8478ec11f505fd146e211d9.jpg, createdBy=3d5e2288124, createdName=121dde13m89暂无昵称, createdTime=Fri Mar 16 21:12:19 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296857, encodeId=696129685e6f, content=确实好多病人都不会用药.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/20/325f09b1de43bf0f9a34e0f300559c38.jpg, createdBy=99df2253231, createdName=驹迷一生, createdTime=Fri Mar 16 18:59:25 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296838, encodeId=c4ff29683886, content=奥美拉唑的确应用.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 16 17:18:40 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-17 ms2296823935859672

    学习了.感谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1672311, encodeId=294116e23111f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat May 12 05:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284406, encodeId=7b611284406e1, content=<a href='/topic/show?id=3db5445e031' target=_blank style='color:#2F92EE;'>#奥美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44570, encryptionId=3db5445e031, topicName=奥美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Mar 18 06:38:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297217, encodeId=870829e217dd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Mar 18 00:11:42 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297152, encodeId=5c6e29e152ea, content=学习了.感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Sat Mar 17 18:51:20 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296995, encodeId=fa50296995cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:41:13 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296992, encodeId=8a0029699257, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:37:11 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296871, encodeId=9b4b2968e1dd, content=一般用波立维的病人我们也是用波立特, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/16/a3f6b823a8478ec11f505fd146e211d9.jpg, createdBy=3d5e2288124, createdName=121dde13m89暂无昵称, createdTime=Fri Mar 16 21:12:19 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296857, encodeId=696129685e6f, content=确实好多病人都不会用药.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/20/325f09b1de43bf0f9a34e0f300559c38.jpg, createdBy=99df2253231, createdName=驹迷一生, createdTime=Fri Mar 16 18:59:25 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296838, encodeId=c4ff29683886, content=奥美拉唑的确应用.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 16 17:18:40 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-17 121832a9m88暂无昵称

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1672311, encodeId=294116e23111f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat May 12 05:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284406, encodeId=7b611284406e1, content=<a href='/topic/show?id=3db5445e031' target=_blank style='color:#2F92EE;'>#奥美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44570, encryptionId=3db5445e031, topicName=奥美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Mar 18 06:38:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297217, encodeId=870829e217dd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Mar 18 00:11:42 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297152, encodeId=5c6e29e152ea, content=学习了.感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Sat Mar 17 18:51:20 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296995, encodeId=fa50296995cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:41:13 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296992, encodeId=8a0029699257, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:37:11 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296871, encodeId=9b4b2968e1dd, content=一般用波立维的病人我们也是用波立特, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/16/a3f6b823a8478ec11f505fd146e211d9.jpg, createdBy=3d5e2288124, createdName=121dde13m89暂无昵称, createdTime=Fri Mar 16 21:12:19 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296857, encodeId=696129685e6f, content=确实好多病人都不会用药.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/20/325f09b1de43bf0f9a34e0f300559c38.jpg, createdBy=99df2253231, createdName=驹迷一生, createdTime=Fri Mar 16 18:59:25 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296838, encodeId=c4ff29683886, content=奥美拉唑的确应用.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 16 17:18:40 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-17 121832a9m88暂无昵称

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1672311, encodeId=294116e23111f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat May 12 05:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284406, encodeId=7b611284406e1, content=<a href='/topic/show?id=3db5445e031' target=_blank style='color:#2F92EE;'>#奥美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44570, encryptionId=3db5445e031, topicName=奥美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Mar 18 06:38:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297217, encodeId=870829e217dd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Mar 18 00:11:42 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297152, encodeId=5c6e29e152ea, content=学习了.感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Sat Mar 17 18:51:20 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296995, encodeId=fa50296995cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:41:13 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296992, encodeId=8a0029699257, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:37:11 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296871, encodeId=9b4b2968e1dd, content=一般用波立维的病人我们也是用波立特, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/16/a3f6b823a8478ec11f505fd146e211d9.jpg, createdBy=3d5e2288124, createdName=121dde13m89暂无昵称, createdTime=Fri Mar 16 21:12:19 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296857, encodeId=696129685e6f, content=确实好多病人都不会用药.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/20/325f09b1de43bf0f9a34e0f300559c38.jpg, createdBy=99df2253231, createdName=驹迷一生, createdTime=Fri Mar 16 18:59:25 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296838, encodeId=c4ff29683886, content=奥美拉唑的确应用.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 16 17:18:40 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-16 121dde13m89暂无昵称

    一般用波立维的病人我们也是用波立特

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1672311, encodeId=294116e23111f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat May 12 05:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284406, encodeId=7b611284406e1, content=<a href='/topic/show?id=3db5445e031' target=_blank style='color:#2F92EE;'>#奥美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44570, encryptionId=3db5445e031, topicName=奥美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Mar 18 06:38:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297217, encodeId=870829e217dd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Mar 18 00:11:42 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297152, encodeId=5c6e29e152ea, content=学习了.感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Sat Mar 17 18:51:20 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296995, encodeId=fa50296995cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:41:13 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296992, encodeId=8a0029699257, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:37:11 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296871, encodeId=9b4b2968e1dd, content=一般用波立维的病人我们也是用波立特, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/16/a3f6b823a8478ec11f505fd146e211d9.jpg, createdBy=3d5e2288124, createdName=121dde13m89暂无昵称, createdTime=Fri Mar 16 21:12:19 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296857, encodeId=696129685e6f, content=确实好多病人都不会用药.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/20/325f09b1de43bf0f9a34e0f300559c38.jpg, createdBy=99df2253231, createdName=驹迷一生, createdTime=Fri Mar 16 18:59:25 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296838, encodeId=c4ff29683886, content=奥美拉唑的确应用.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 16 17:18:40 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-16 驹迷一生

    确实好多病人都不会用药.学习了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1672311, encodeId=294116e23111f, content=<a href='/topic/show?id=2f3a8e59170' target=_blank style='color:#2F92EE;'>#药效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87591, encryptionId=2f3a8e59170, topicName=药效)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=189026903389, createdName=lsndxfj, createdTime=Sat May 12 05:38:00 CST 2018, time=2018-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284406, encodeId=7b611284406e1, content=<a href='/topic/show?id=3db5445e031' target=_blank style='color:#2F92EE;'>#奥美拉唑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44570, encryptionId=3db5445e031, topicName=奥美拉唑)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Mar 18 06:38:00 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297217, encodeId=870829e217dd, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sun Mar 18 00:11:42 CST 2018, time=2018-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=297152, encodeId=5c6e29e152ea, content=学习了.感谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/13/c36860368f59b7f042bac242c6785040.jpg, createdBy=457b1858657, createdName=ms2296823935859672, createdTime=Sat Mar 17 18:51:20 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296995, encodeId=fa50296995cd, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:41:13 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296992, encodeId=8a0029699257, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Mar 17 06:37:11 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296871, encodeId=9b4b2968e1dd, content=一般用波立维的病人我们也是用波立特, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/16/a3f6b823a8478ec11f505fd146e211d9.jpg, createdBy=3d5e2288124, createdName=121dde13m89暂无昵称, createdTime=Fri Mar 16 21:12:19 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296857, encodeId=696129685e6f, content=确实好多病人都不会用药.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/20/325f09b1de43bf0f9a34e0f300559c38.jpg, createdBy=99df2253231, createdName=驹迷一生, createdTime=Fri Mar 16 18:59:25 CST 2018, time=2018-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=296838, encodeId=c4ff29683886, content=奥美拉唑的确应用.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Fri Mar 16 17:18:40 CST 2018, time=2018-03-16, status=1, ipAttribution=)]
    2018-03-16 1e0f8808m18(暂无匿称)

    奥美拉唑的确应用.学习了.

    0

相关资讯

JGH:延长阿莫西林和奥美拉唑二联治疗HP的时间至6周

文献标题:Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. 文献出处:J Gastroenterol Hepatol. 2012 Jan;27(1):59-61. 期刊影响因子:34.4幽门螺杆菌(HP)对抗

关于奥美拉唑,你还有疑问吗?

1、奥美拉唑的作用机理是什么?老百姓特别想知道很多药它是怎么来治病的,对于奥美拉唑来说,它用专业的词汇就是说,它能够抑制一个叫胃H+-K+-ATP酶,又叫质子泵。简单的说就是这个泵,它能够把钾离子泵到细胞内,把细胞内的氢离子泵出来,然后这个氢离子释放到胃中,就形成了我们所说的胃酸。奥美拉唑就是抑制了这个泵,让这个泵不能把氢离子泵出来,这种情况下,就造成了这个胃内的PH升高,把胃酸环境降下去,起